ProQR Therapeutics N.V.
PRQR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $4 | $5 | $4 |
| % Growth | -23.6% | -15.5% | 4.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $4 | $5 | $4 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $11 | $11 | $12 | $11 |
| G&A Expenses | $3 | $5 | $3 | $4 |
| SG&A Expenses | $3 | $5 | $3 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $14 | $16 | $15 | $14 |
| Operating Income | -$11 | -$12 | -$11 | -$10 |
| % Margin | -387.1% | -320.9% | -239.3% | -234.1% |
| Other Income/Exp. Net | $0 | $0 | $1 | $1 |
| Pre-Tax Income | -$11 | -$12 | -$10 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$12 | -$10 | -$9 |
| % Margin | -377.6% | -319.1% | -223% | -216% |
| EPS | -0.1 | -0.12 | -0.1 | -0.11 |
| % Growth | 16.7% | -20% | 9.1% | – |
| EPS Diluted | -0.1 | -0.12 | -0.1 | -0.11 |
| Weighted Avg Shares Out | 105 | 105 | 105 | 82 |
| Weighted Avg Shares Out Dil | 110 | 105 | 105 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$10 | -$12 | -$10 | -$6 |
| % Margin | -354.5% | -303.2% | -224.3% | -135.2% |